Reply.
We sincerely thank Dr. Vikas Taneja for his interest in our paper and are more than happy to welcome different perspectives and interpretations on the study. We would, however, like to offer humble corrections to Dr. Taneja's two assumptions in his review: (1) that participants in the insulin glargine group had more severe steatohepatitis at baseline compared to the other two groups and (2) that optimal glycemic control was not achieved. As shown in our study, similar baseline characteristics were observed across all three treatment groups, including diabetes duration, magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT).